ifosfamide has been researched along with Diffuse Parenchymal Lung Disease in 1 studies
Excerpt | Relevance | Reference |
---|---|---|
"Ifosfamide is an active alkylating agent used in the first-line treatment of NSCLC." | 2.71 | Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel. ( Chen, MC; Chen, YM; Lee, CS; Lin, WC; Perng, RP; Shih, JF; Tsai, CM, 2003) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, YM | 1 |
Shih, JF | 1 |
Lee, CS | 1 |
Chen, MC | 1 |
Lin, WC | 1 |
Tsai, CM | 1 |
Perng, RP | 1 |
1 trial available for ifosfamide and Diffuse Parenchymal Lung Disease
Article | Year |
---|---|
Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2003 |